What is a critical safety consideration when administering intrathecal chemotherapy?

• A. It must be administered intrathecally using drugs approved for intrathecal use; never IV; use dedicated syringes and route labeling.
• B. It can be injected intravenously if needed.
• C. Any syringe may be used.
• D. It can be given via the oral route.

Answer: (A)

Administering intrathecal chemotherapy requires strict control of both the drug and the route. Only agents formulated and approved specifically for intrathecal use should be given into the intrathecal space, and they must be delivered by the correct route with dedicated syringes and clearly labeled administration to avoid dangerous mix-ups. Why this matters is that the intrathecal space (the CSF around the spinal cord) is highly sensitive, and many drugs designed for systemic or IV use can be profoundly neurotoxic if given by the wrong route or in the wrong preparation. IV administration would not reliably reach the CSF and can cause severe systemic toxicity, while oral administration isn’t feasible for these agents. Using any syringe or failing to label correctly increases the risk of administering the drug via the wrong route, which can be catastrophic. So the safest practice is to use intrathecal-specific, approved formulations, given by the correct route, with dedicated equipment and proper labeling to ensure patient safety.